CME

Faculty: Adam J. Luginbuhl, MD

Faculty: Jennifer Johnson, MD, PhD

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

Faculty: Honey East, MD

Faculty: Amir H. Hamrahian, MD

Faculty: Rosario Pivonello, MD, PhD

This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of CS, as well as approaches to managing mild cases. The program will then build on these fundamentals by applying them to real-world treatment scenarios.

Faculty: Hanford Yau, MD, CCD, FACP, FACE

Faculty: Eden Miller, DO

With an updated understanding of how common hypercortisolism is among patients with hard-to-manage cardiometabolic conditions, what are the implications for clinical practice? How can healthcare providers determine who should be screened, carry out straightforward screening, and confirm a diagnosis? And once hypercortisolism is identified, what are the next steps? Join our experts as they walk through a step-by-step approach to screening and diagnosis, followed by a discussion of appropriate next actions.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

Drs. Neeraj Agarwal and Rana McKay discuss treatment intensification strategies in metastatic castration-sensitive prostate cancer (mCSPC), with a focus on combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs) and chemotherapy. They review key clinical trial data supporting doublet and triplet regimens that improve overall survival and other clinically meaningful outcomes. The faculty examine how disease burden, metastatic pattern, genomic features, comorbidities, and patient fitness inform selection of doublet versus triplet therapy. They also highlight multidisciplinary approaches to managing treatment-related adverse events and preserving quality of life in patients receiving intensified treatment.

Faculty: Anthony Fernandez, MD, PhD

Generalized pustular psoriasis (GPP) can look familiar but missing it can have serious consequences. Uncover how IL-36 signaling and immune dysregulation shape disease presentation, progression, and treatment response. You’ll learn to distinguish GPP from other neutrophilic dermatoses using clinical clues, biomarkers, and diagnostic tools. Explore how emerging targeted therapies are changing what’s possible for patients who previously had limited options. Real-world strategies will help you build comprehensive, long-term management plans that go beyond symptom control. If you’ve ever second-guessed a pustular case, this activity will sharpen your clinical instincts.

Faculty: Patrick Rossignol, MD, PhD

Faculty: Julio Núñez, MD, PhD

Iron deficiency and iron-deficiency anemia are related but distinct clinical entities, with iron deficiency often preceding or occurring independently of anemia. In chronic kidney disease (CKD), inflammation-driven iron sequestration and impaired iron availability frequently develop before hemoglobin declines, making hemoglobin-only screening insufficient. Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD highlight the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD, along with the need for proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selection of iron replacement strategies to improve long-term patient outcomes.

Host: Jessica Allegretti, MD, MPH, FACG, AGAF

Guest: Jordan E. Axelrad, MD, MPH, AGAF, FACG, FCCF

Guest: Russell D. Cohen, MD, FACG, AGAF

On-demand webcast on the latest advances in managing inflammatory bowel disease (IBD) and expert-informed strategies for providing guideline-concordant care to patients with IBD.

Host: Mara Fiorio, DCN, RD, LD, BC-ADM, CDCES

Guest: Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP

Guest: Richard E. Pratley, MD

Learn how to optimize guideline-concordant care for patients with type 2 diabetes with this on-demand webcast—featuring the latest data on weekly insulin therapies and expert-informed strategies to support the future integration of these emerging agents in your practice.

Faculty: David T. Rubin, MD

Faculty: Michael Dolinger, MD, MBA

In this case-based discussion, Drs. Dolinger and Rubin examine the diagnostic approach to patients presenting with signs and symptoms suggestive of inflammatory bowel disease (IBD). The conversation explores key steps in the initial evaluation, appropriate laboratory testing, the role of colonoscopy versus additional noninvasive work-up, and how imaging modalities such as intestinal ultrasound contribute to disease characterization. The faculty also address methods to assess disease severity and activity, incorporating clinical indices, endoscopic findings, and risk stratification.

Faculty: Karen E. Anderson, MD

Faculty: Hubert H. Fernandez, MD

This Podcast Plus discussion examines how to distinguish tardive dyskinesia (TD) from other movement disorders using clinical features, medication timing, and response patterns. Key characteristics of TD, including irregular orofacial movements, are compared with drug-induced parkinsonism and akathisia. The discussion highlights the delayed onset of TD following dopamine receptor-blocking agents and compares timing across movement syndromes. It also emphasizes why TD should not be grouped with other extrapyramidal symptoms, as it may be missed, masked, or coexist with other conditions, affecting treatment decisions.